Cell cycle clock and its dysregulation in bronchogenic cancer;L'horloge du cycle cellulaire et sa dysregulation au cours des cancers bronchopulmonaires

Revue de Pneumologie Clinique

Volumn 53, Issue 1, 1997, Pages 7-11

  Brechot, J M ^a  

^a HÔTEL DIEU   (France)

Author keywords

bronchogenic cancer; cell cycle; oncogenesis

Indexed keywords

BRONCHUS CANCER; CELL CYCLE; HUMAN; LUNG CARCINOGENESIS; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

BIOLOGICAL CLOCKS; CELL CYCLE; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS;

EID: 0030889860     PISSN: 00325821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Weinberg R. A.: The integration of molecular genetics into cancer management. Cancer, 1992, 70, 1653-58.
2. Hunter T., Pines J.: cyclins and cancer (II): cyclin D and CDK inhibitors come of age. Cell, 1994, 79, 573-82.
3. Bates S., Peters G.: Cyclin D1 as a cellular proto-oncogene. Semin Cancer Biol, 1995, 6, 73-82.
4. Pines J.: Cyclins, CDKs and cancer. Semin Cancer Biol, 1995, 6, 63-72.
5. Canman C. E., Kastan M. B.: Induction of apoptosis by tumor suppressor genes and oncogenes. Semin Cancer Biol, 1995, 6, 17-25.
6. Jacks T., Weinberg R. A.: Cell-cycle control and its watchman. Nature, 1996, 381, 643-4.
7. Lane D. P.: p53, guardian of the genome. Nature, 1992, 358, 15-6.
8. Whyte P.: The retinoblastoma protein and its relatives. Semin Cancer Biol, 1995, 6, 83-90.
9. Kouzarides T.: Transcriptional control by the retinoblastoma protein. Semin Cancer Biol, 1995, 6, 91-8.
10. Cao L., Faha B., Dembski M., Tsai L.-H., Harlow E., Dyson N.: Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature, 1992, 355, 176-79.
11. Adams P. D., Kaelin W. G.: Transcriptional control by E2F. Semin Cancer Biol, 1995, 6, 99-108.
12. Devereux T. R. Taylor J. A., Barrett J. C.: Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Chest, 1996, 109, 14-19S.
13. Reissmann P. T., Koga H., Ramos L., Figlin R., Holmes E. C., Slamon D. J.: Amplification and overexpression of cyclin D1 and epidermal growth factor receptor in NSCLC. AACR Proceedings, Washington 1996, 3895 (abst).
14. Wang J., Zindy F., Chenivesse X., Lamas E., Henglein B., Brechot C.: Modification for cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene, 1992, 7, 653-6.
15. Packenham J. P., Taylor J. A., White C. M., Anna C. H., Barrett J. C., Devereux T. R.: Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non small cell lung cancers. Clin Cancer Res, 1995, 1, 687-90.
16. Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi To, Takahashi Ta.: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non small cell lung cancers. Cancer Res, 1995, 55, 514-17.
17. INK4B/MTS2, and p18 genes in primary and metastatic lung cancers. Cancer Res, 1995, 55, 1448-51.
18. Shimizu T., Miwa W., Nakamori S.: Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn J Cancer Res, 1996, 87, 275-8.
19. Levine A. J., Momand J., Finlay C.: The p53 tumour suppressor gene. Science, 1991, 351, 453-6.
20. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C.: Mutations in the p53 tumor suppressor gene: clues to cancer etiologies and molecular pathogenesis. Cancer Res, 1994, 54, 4855-78.
21. Weinberg R. A.: The retinoblastoma gene and gene product. Cancer Surveys, 1992, 12, 43-57.
22. Nevins I. R.: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science, 1992, 258, 424-29.
23. Ottarson G. A., Kratzke R. A., Coxon A. et al.: Absence of p16NK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 1994, 9, 3375-8.